(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 287.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.4%.
Humacyte's revenue in 2026 is $2,038,000.On average, 9 Wall Street analysts forecast HUMA's revenue for 2026 to be $2,462,191,908, with the lowest HUMA revenue forecast at $1,523,051,081, and the highest HUMA revenue forecast at $3,527,217,569. On average, 8 Wall Street analysts forecast HUMA's revenue for 2027 to be $8,578,152,276, with the lowest HUMA revenue forecast at $5,765,836,235, and the highest HUMA revenue forecast at $11,469,507,119.
In 2028, HUMA is forecast to generate $29,577,385,568 in revenue, with the lowest revenue forecast at $16,155,220,394 and the highest revenue forecast at $44,013,067,970.